AMPK Activation by ASP4132 Inhibits Non-small Cell Lung Cancer Cell Growth

In primary NSCLC cells and established cell lines ASP4132 potently inhibited cell growth, proliferation and cell cycle progression as well as cell migration and invasion.
[Cell Death & Disease]
Xia, Y., Zha, J., Sang, Y.-H., Yin, H., Xu, G., Zhen, J., Zhang, Y., & Yu, B. (2021). AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth. Cell Death & Disease, 12(4), 1–14. https://doi.org/10.1038/s41419-021-03655-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share

LncRNA UCC Promotes Epithelial–Mesenchymal Transition via the miR-143-3p/SOX5 Axis in Non-Small-Cell Lung Cancer

A dual-luciferase reporter system and RIP assays showed that UCC specifically bound to miR-143-3p and acted as a sponge of miR-143-3p in NSCLC cells.
[Laboratory Investigation]
Chen, R., Zhang, C., Cheng, Y., Wang, S., Lin, H., & Zhang, H. (2021). LncRNA UCC promotes epithelial–mesenchymal transition via the miR-143-3p/SOX5 axis in non-small-cell lung cancer. Laboratory Investigation, 1–13. https://doi.org/10.1038/s41374-021-00586-6 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics

Sorrento Therapeutics, Inc. announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA Therapeutics, Inc. The acquisition will include late clinical stage drug Abivertinib, clinical stage candidate AC0058, preclinical stage candidate AC0939, and ACEA’s extensive proprietary library of small molecules, which potentially have applications for numerous human disease indications, including non-small cell lung cancer, B cell lymphomas, systemic lupus, rheumatoid arthritis, multiple sclerosis and viral infections.
[Sorrento Therapeutics, Inc. (Globe Newswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

Fusion Proteins in Lung Cancer: Addressing Diagnostic Problems for Deciding Therapy

The authors explore current diagnostic problems of gene fusion detection relative to the technologies available, in order to clarify future standardization of analyses which determine therapeutic choices.
[Expert Review of Anticancer Therapy]
Marino, F. Z., Alì, G., Facchinetti, F., Righi, L., Fontanini, G., Rossi, G., & Franco, R. (2021). Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy. Expert Review of Anticancer Therapy, 0(0), 1–14. https://doi.org/10.1080/14737140.2021.1903875 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Roche Receives Positive CHMP Opinion for Tecentriq as a First-Line Monotherapy Treatment for People with a Type of Metastatic Non-Small Cell Lung Cancer

Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Tecentriq® as a first-line treatment for adults with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression, with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.
[Roche]
Press Release
Bookmark

No account yet? Register

0
Share

Long Noncoding RNA McF2l-AS1 Promotes the Cancer Stem Cell-Like Traits in Non-Small Cell Lung Cancer Cells through Regulating miR-873-5p Level

Functional experiments showed that MCF2L‐AS1 knockdown suppressed the cancer stem cell‐like traits of non-small cell lung cancer cells through qRT‐PCR, western blot, tumor‐sphere formation, and ALDH activity detection.
[Environmental Toxicology]
Li, S., & Lin, L. (n.d.). Long noncoding RNA MCF2L-AS1 promotes the cancer stem cell-like traits in non-small cell lung cancer cells through regulating miR-873-5p level. Environmental Toxicology, n/a(n/a). https://doi.org/https://doi.org/10.1002/tox.23142 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Zinc‐Finger E‐Box‐Binding Homeobox 1 (ZEB1) Plays a Crucial Role in the Maintenance of Lung Cancer Stem Cells Resistant to Gefitinib

PC9 and HCC827 non‐small cell lung cancer cell lines were treated with high concentrations of gefitinib, and surviving cells were referred to as “gefitinib‐resistant persisters” (GRPs). Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) knockdown or overexpression was performed to determine the biological significance of ZEB1 in the cancer stem cell features of GRPs, and animal models were studied for in vivo validation.
[Thoracic Cancer]
Nurwidya, F., Takahashi, F., Winardi, W., Tajima, K., Mitsuishi, Y., Murakami, A., Kobayashi, I., Nara, T., Hashimoto, M., Kato, M., Hidayat, M., Suina, K., Hayakawa, D., Asao, T., Ko, R., Shukuya, T., Yae, T., Shimada, N., Yoshioka, Y., … Takahashi, K. (n.d.). Zinc-finger E-box-binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib. Thoracic Cancer, n/a(n/a). https://doi.org/https://doi.org/10.1111/1759-7714.13937 Cite
Full Article
Bookmark

No account yet? Register

0
Share

MZT2A Promotes NSCLC Viability and Invasion by Increasing Akt Phosphorylation via the MOZART2 Domain

Scientists showed that mitotic spindle organizing protein 2A (MZT2A) exhibited oncogenic activity by activating galectin‐3‐binding protein and Akt in NSCLC.
[Cancer Science]
Wang, H., Jiang, X., Cheng, Y., Ren, H., Hu, Y., Zhang, Y., Su, H., Zou, Z., Wang, Q., Liu, Z., Zhang, J., & Qiu, X. (n.d.). MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain. Cancer Science, n/a(n/a). https://doi.org/https://doi.org/10.1111/cas.14900 Cite
Abstract
Bookmark

No account yet? Register

0
Share

miR‑454‑3p Inhibits Non‑Small Cell Lung Cancer Cell Proliferation and Metastasis by Targeting TGFB2

miR‑454‑3p overexpression led to the suppression of proliferation, migration, and invasion in A549 and NCI‑H1650 cells. The overexpression of miR‑454‑3p in A549 and NCI‑H1650 cells significantly inhibited EMT. TGFB2 was revealed to be a direct target of miR‑454‑3p by using TargetScan database and luciferase reporter assay.
[Oncology Reports]
Liao, H., Liang, Y., Kang, L., Xiao, Y., Yu, T., & Wan, R. (2021). miR‑454‑3p inhibits non‑small cell lung cancer cell proliferation and metastasis by targeting TGFB2. Oncology Reports, 45(5), 1–12. https://doi.org/10.3892/or.2021.8018 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Musashi-2 (MSI2) Regulates Epidermal Growth Factor Receptor (EGFR) Expression and Response to EGFR Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Musashi-2 (MSI2) control of epidermal growth factor receptor (EGFR) expression and activity in an NSCLC cell line panel was studied using RT-PCR, Western blots, and RNA immunoprecipitation. Functional consequences of MSI2 depletion were explored for cell growth and response to EGFR-targeting drugs, in vitro and in vivo.
[Oncogenesis]
Makhov, P., Bychkov, I., Faezov, B., Deneka, A., Kudinov, A., Nicolas, E., Brebion, R., Avril, E., Cai, K. Q., Kharin, L. V., Voloshin, M., Frantsiyants, E., Karnaukhov, N., Kit, O. I., Topchu, I., Fazliyeva, R., Nikonova, A. S., Serebriiskii, I. G., Borghaei, H., … Boumber, Y. (2021). Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC). Oncogenesis, 10(3), 1–14. https://doi.org/10.1038/s41389-021-00317-y Cite
Full Article
Bookmark

No account yet? Register

0
Share

Uncommon Targets in Non-Small Cell Lung Cancer: Everyone Wants a Slice of Cake

In this review, scientists discuss some uncommon alterations in NSCLC such as ROS1, BRAF, RET, HER2, NTRK, MET and other targets that are in an early evaluation phase.
[Critical Reviews in Oncology/Hematology]
De Toma, A., Lo Russo, G., Signorelli, D., Pagani, F., Randon, G., Galli, G., Prelaj, A., Ferrara, R., Proto, C., Ganzinelli, M., Zilembo, N., de Braud, F., & Garassino, M. C. (2021). Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Critical Reviews in Oncology/Hematology, 160, 103299. https://doi.org/10.1016/j.critrevonc.2021.103299 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share